MX354846B - Metodos para tratar gota en sub-poblaciones de pacientes. - Google Patents

Metodos para tratar gota en sub-poblaciones de pacientes.

Info

Publication number
MX354846B
MX354846B MX2014005399A MX2014005399A MX354846B MX 354846 B MX354846 B MX 354846B MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 354846 B MX354846 B MX 354846B
Authority
MX
Mexico
Prior art keywords
methods
treating gout
patient subpopulations
subject
subpopulations
Prior art date
Application number
MX2014005399A
Other languages
English (en)
Other versions
MX2014005399A (es
Inventor
Edward Lavan Brian
chandra saha Gopal
K Roberts Brian
A Mcwherter Charles
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014005399A publication Critical patent/MX2014005399A/es
Publication of MX354846B publication Critical patent/MX354846B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En una modalidad, la presente solicitud describe un método para reducir el nivel de ácido úrico en suero en un sujeto con una función renal dañada, que comprende administrar a los sujetos un compuesto de la Fórmula (I), como aquí se describe.
MX2014005399A 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes. MX354846B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
MX2014005399A MX2014005399A (es) 2015-04-08
MX354846B true MX354846B (es) 2018-03-22

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005399A MX354846B (es) 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes.

Country Status (14)

Country Link
EP (1) EP2775835A4 (es)
JP (1) JP6047172B2 (es)
KR (1) KR101848122B1 (es)
CN (1) CN104066323A (es)
AU (1) AU2011380509B2 (es)
BR (1) BR112014010693A2 (es)
CA (1) CA2859689C (es)
CL (1) CL2014001156A1 (es)
IL (1) IL232385A (es)
MX (1) MX354846B (es)
NZ (1) NZ624714A (es)
SG (1) SG11201402027PA (es)
WO (1) WO2013066352A1 (es)
ZA (1) ZA201403574B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002799A (ko) * 2012-04-13 2015-01-07 사이머베이 쎄라퓨틱스, 인코퍼레이티드 할로페네이트 또는 할로펜산 및 소염제를 이용한 통풍 환자에서의 고요산혈증 치료 방법
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防尿路结石的饲料添加剂
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
CN111246852A (zh) * 2017-10-26 2020-06-05 大塚制药株式会社 含有磷酸肌醇的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
EA201270666A1 (ru) * 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты

Also Published As

Publication number Publication date
WO2013066352A1 (en) 2013-05-10
CL2014001156A1 (es) 2015-01-16
MX2014005399A (es) 2015-04-08
EP2775835A1 (en) 2014-09-17
AU2011380509A1 (en) 2014-05-29
AU2011380509B2 (en) 2016-05-19
EP2775835A4 (en) 2015-07-29
CA2859689C (en) 2018-05-22
ZA201403574B (en) 2015-11-25
BR112014010693A2 (pt) 2020-11-10
CN104066323A (zh) 2014-09-24
JP2014532759A (ja) 2014-12-08
CA2859689A1 (en) 2013-05-10
KR101848122B1 (ko) 2018-04-11
JP6047172B2 (ja) 2016-12-21
KR20140123927A (ko) 2014-10-23
IL232385A (en) 2017-10-31
IL232385A0 (en) 2014-06-30
NZ624714A (en) 2016-01-29
SG11201402027PA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA201591527A1 (ru) Новые производные пиридина
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
TN2013000347A1 (en) Production method of optically active dihydrobenzofuran derivative
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2013012785A (es) Tratamiento del mieloma multiple.
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
BR112013005810A2 (pt) métodos para reduzir a concentração de lactato no sangue
GEP20166448B (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
MX349373B (es) Nuevos derivados de pirazina.
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
PH12014500990A1 (en) Methods for treating gout flares
MX354846B (es) Metodos para tratar gota en sub-poblaciones de pacientes.
GB201107985D0 (en) Process
FR2980708B1 (fr) Composition comprenant un gallotannin
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX2012003290A (es) Composicion para reducir el nivel de acido urico en la sangre.
WO2013090319A3 (en) Treatment of type i and type ii diabetes
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2013006066A (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.

Legal Events

Date Code Title Description
FG Grant or registration